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Abstract
Pattern Recognition Receptors (PRRs, [83]) (nomenclature as agreed by NC-IUPHAR sub-committee on
Pattern Recognition Receptors, [15]) participate in the innate immune response to microbial agents, the
stimulation of which leads to activation of intracellular enzymes and regulation of gene transcription. PRRs
express multiple leucine-rich regions to bind a range of microbially-derived ligands, termed PAMPs or pathogen-
associated molecular patterns or endogenous ligands, termed DAMPS or damage-associated molecular
patterns. These include peptides, carbohydrates, peptidoglycans, lipoproteins, lipopolysaccharides, and nucleic
acids. PRRs include both cell-surface and intracellular proteins. PRRs may be divided into signalling-associated
members, identified here, and endocytic members, the function of which appears to be to recognise particular
microbial motifs for subsequent cell attachment, internalisation and destruction. Some are involved in
inflammasome formation, and modulation of IL-1β cleavage and secretion, and others in the initiation of the type
I interferon response. 
PRRs included in the Guide To PHARMACOLOGY are:
Catalytic PRRs (see links below this overview)
Toll-like receptors (TLRs)
Nucleotide-binding oligomerization domain, leucine-rich repeat containing receptors (NLRs, also known as NOD
(Nucleotide oligomerisation domain)-like receptors)
RIG-I-like receptors (RLRs)
Caspase 4 and caspase 5 
Non-catalytic PRRs
Absent in melanoma (AIM)-like receptors (ALRs)
C-type lectin-like receptors (CLRs)
Other pattern recognition receptors
Advanced glycosylation end-product specific receptor (RAGE)
Contents
This is a citation summary for Pattern recognition receptors in the Guide to Pharmacology database (GtoPdb). It
exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by
citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are
given here under database links.
1
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current





    Toll-like receptor family
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=316
        Receptors
                TLR1
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1751
                TLR2
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1752
                TLR3
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753
                TLR4
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754
                TLR5
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1755
                TLR6
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1756
                TLR7
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757
                TLR8
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1758
                TLR9
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759
                TLR10
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1760
                TLR11
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1761
    NOD-like receptor family
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=317
        Receptors
                NOD1(nucleotide binding oligomerization domain containing 1)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1762
                NOD2(nucleotide binding oligomerization domain containing 2)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1763
                NLRC3
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1764
                NLRC4
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1782
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                NLRC5
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1765
                NLRX1
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1766
                CIITA
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1767
                NLRP1
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1768
                NLRP2
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1769
                NLRP3
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1770
                NLRP4
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1771
                NLRP5
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1772
                NLRP6
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1773
                NLRP7
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1774
                NLRP8
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1775
                NLRP9
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1776
                NLRP10
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1777
                NLRP11
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1778
                NLRP12
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1779
                NLRP13
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1780
                NLRP14
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1781
    RIG-I-like receptor family
    http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=940
        Receptors
                RIG-1(DExD/H-box helicase 58)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2920
                MDA5(interferon induced with helicase C domain 1)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2921
                LGP2(DExH-box helicase 58)
                http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2922
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